Table 2.
Sociodemographic characteristics and clinical details of the patients with renal dysfunction experiencing potential drug-drug interaction
| Characteristics | n (%) |
|---|---|
| Age (years), mean±SD | 53.8±17.5 |
| Age categories | |
| ≤30 | 7 (11.5) |
| 31-40 | 9 (14.8) |
| 41-50 | 7 (11.5) |
| 51-60 | 12 (19.7) |
| ≥61 | 26 (42.6) |
| Gender | |
| Male | 34 (55.7) |
| Female | 27 (44.3) |
| Ethnicity | |
| Yoruba | 27 (44.3) |
| Igbo | 21 (34.4) |
| Hausa | 13 (21.3) |
| Kidney disease types | |
| Hypertensive nephropathy | 20 (32.8) |
| Diabetic nephropathy | 14 (22.9) |
| Chronic glomerulonephritis | 8 (13.1) |
| Obstructive uropathy | 11 (18) |
| Others | 8 (13.1) |
| Comorbid conditions | |
| Hypertension | 21 (34.4) |
| Diabetes | 16 (26.2) |
| Cardiovascular diseases | 14 (22.9) |
| Sepsis | 10 (16.4) |
| Presence of potential DDI | 508 (93.8) |
| Mean pill/day | 15.1±6.9 |
| Median pill/day | 14 (4-30) |
| Pill burden ˃25/day | 9 (14.8) |
Others refer to HIV nephropathy (3.2%), sickle cell nephropathy (4.1%), and toxic nephropathy (5.8%). DDI – Drug–drug interaction; SD – Standard deviation